Advertisement

Heart Failure Reviews

, Volume 24, Issue 2, pp 189–197 | Cite as

Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical impact, and management

  • Lohit GargEmail author
  • Manasvi Gupta
  • Syed Rafay Ali Sabzwari
  • Sahil Agrawal
  • Manyoo Agarwal
  • Talha Nazir
  • Jeffrey Gordon
  • Babak Bozorgnia
  • Matthew W. Martinez
Article
  • 174 Downloads

Abstract

Hypertrophic cardiomyopathy (HCM) is the most common hereditary cardiomyopathy characterized by left ventricular hypertrophy and spectrum of clinical manifestation. Atrial fibrillation (AF) is a common sustained arrhythmia in HCM patients and is primarily related to left atrial dilatation and remodeling. There are several clinical, electrocardiographic (ECG), and echocardiographic (ECHO) features that have been associated with development of AF in HCM patients; strongest predictors are left atrial size, age, and heart failure class. AF can lead to progressive functional decline, worsening heart failure and increased risk for systemic thromboembolism. The management of AF in HCM patient focuses on symptom alleviation (managed with rate and/or rhythm control methods) and prevention of complications such as thromboembolism (prevented with anticoagulation). Finally, recent evidence suggests that early rhythm control strategy may result in more favorable short- and long-term outcomes.

Keywords

Atrial fibrillation Hypertrophic cardiomyopathy Treatment Antiarrhythmic agents 

Notes

Compliance with ethical standards

Conflict of interest

The authors declare that they have no conflict of interest.

Ethical approval

This article does not contain any studies with human participants or animals performed by any of the authors.

Supplementary material

10741_2018_9752_MOESM1_ESM.docx (126 kb)
Supplementary Table 1 (DOCX 126 kb)

References

  1. 1.
    Maron BJ, Maron MS (2013) Hypertrophic cardiomyopathy. Lancet 381(9862):242–255.  https://doi.org/10.1016/S0140-6736(12)60397-3.Epub2012Aug 6.Review.PubMedPMID:22874472
  2. 2.
    Jacoby D, McKenna WJ (2012) Genetics of inherited cardiomyopathy. Eur Heart J 33(3):296–304Google Scholar
  3. 3.
    Olivotto I, d’Amati G, Basso C et al (2015) Defining phenotypes and disease progression in sarcomeric cardiomyopathies: contemporary role of clinical investigations. Cardiovasc Res 105(4):409–423Google Scholar
  4. 4.
    Authors/Task Force members, Elliott PM, Anastasakis A et al (2014) ESC Guidelines on diagnosis and management of hypertrophic cardiomyopathy: the Task Force for the Diagnosis and Management of Hypertrophic Cardiomyopathy of the European Society of Cardiology (ESC). Eur Heart J 35(39):2733–2779Google Scholar
  5. 5.
    Gersh BJ, Maron BJ, Bonow RO, Dearani JA, Fifer MA, Link MS, Naidu SS, Nishimura RA, Ommen SR, Rakowski H, Seidman CE, Towbin JA, Udelson JE, Yancy CW (2011) American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines.. 2011 ACCF/AHA Guideline for the Diagnosis and Treatment of Hypertrophic Cardiomyopathy: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Developed in collaboration with the American Association for Thoracic Surgery, American Society of Echocardiography, American Society of Nuclear Cardiology, Heart Failure Society of America, Heart Rhythm Society, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol 58(25):e212–e260Google Scholar
  6. 6.
    Marian AJ, Braunwald E (2017) Hypertrophic Cardiomyopathy: genetics, pathogenesis, clinical manifestations, diagnosis, and therapy. Circ Res 121(7):749–770Google Scholar
  7. 7.
    MacIntyre C, Lakdawala NK (2016) Management of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 133(19):1901–1905Google Scholar
  8. 8.
    Olivotto I, Cecchi F, Casey SA, Dolara A, Traverse JH, Maron BJ (2001) Impact of atrial fibrillation on the clinical course of hypertrophic cardiomyopathy. Circulation 104(21):2517–2524Google Scholar
  9. 9.
    Guttmann OP, Rahman MS, O'Mahony C, Anastasakis A, Elliott PM (2014) Atrial fibrillation and thromboembolism in patients with hypertrophic cardiomyopathy: systematic review. Heart 100(6):465–472Google Scholar
  10. 10.
    Robinson K, Frenneaux MP, Stockins B, Karatasakis G, Poloniecki JD, McKenna WJ (1990) Atrial fibrillation in hypertrophic cardiomyopathy: a longitudinal study. J Am Coll Cardiol 15(6):1279–1285Google Scholar
  11. 11.
    Maron BJ, Maron MS, Semsarian C (2012) Genetics of hypertrophic cardiomyopathy after 20 years: clinical perspectives. J Am Coll Cardiol 60(8):705–715Google Scholar
  12. 12.
    Gruver EJ, Fatkin D, Dodds GA, Kisslo J, Maron BJ, Seidman JG, Seidman CE (1999) Familial hypertrophic cardiomyopathy and atrial fibrillation caused by Arg663His beta-cardiac myosin heavy chain mutation. Am J Cardiol 83(12A):13H–18HGoogle Scholar
  13. 13.
    Tuluce K, Tuluce SY (2015) Predictors of atrial fibrillation risk in hypertrophic cardiomyopathy. J Atr Fibrillation 7(5):1200Google Scholar
  14. 14.
    Nair AG, Fischer AG (2006) Atrial fibrillation in hypertrophic cardiomyopathy: mechanisms, embolic risk and prognosis. Anadolu Kardiyol Derg 6(Suppl 2):40–43Google Scholar
  15. 15.
    Papavassiliu T, Germans T, Flüchter S, Doesch C, Suriyakamar A, Haghi D, Süselbeck T, Wolpert C, Dinter D, Schoenberg SO, van Rossum AC (2009) Borggrefe M. CMR findings in patients with hypertrophic cardiomyopathy and atrial fibrillation. J Cardiovasc Magn Reson 11(34):34Google Scholar
  16. 16.
    Providencia R, Elliott P, Patel K, McCready J, Babu G, Srinivasan N, Bronis K, Papageorgiou N, Chow A, Rowland E, Lowe M, Segal OR, Lambiase PD (2016) Catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: a systematic review and meta-analysis. Heart 102(19):1533–1543Google Scholar
  17. 17.
    Ohtani K, Yutani C, Nagata S, Koretsune Y, Hori M, Kamada T (1995) High prevalence of atrial fibrosis in patients with dilated cardiomyopathy. J Am Coll Cardiol 25(5):1162–1169Google Scholar
  18. 18.
    Prinz C, Van Buuren F, Bogunovic N, Bitter T, Faber L, Horstkotte D (2012) In patients with hypertrophic cardiomyopathy myocardial fibrosis is associated with both left ventricular and left atrial dysfunction. Acta Cardiol 67(2):187–193Google Scholar
  19. 19.
    Alasady M, Shipp NJ, Brooks AG, Lim HS, Lau DH, Barlow D, Kuklik P, Worthley MI, Roberts-Thomson KC, Saint DA, Abhayaratna W, Sanders P (2013) Myocardial infarction and atrial fibrillation: importance of atrial ischemia. Circ Arrhythm Electrophysiol 6(4):738–745Google Scholar
  20. 20.
    Di Donna P, Olivotto I, Delcrè SD, Caponi D, Scaglione M, Nault I, Montefusco A, Girolami F, Cecchi F, Haissaguerre M, Gaita F (2010) Efficacy of catheter ablation for atrial fibrillation in hypertrophic cardiomyopathy: impact of age, atrial remodelling, and disease progression. Europace 12(3):347–355Google Scholar
  21. 21.
    Seet RC, Friedman PA, Rabinstein AA (2011) Prolonged rhythm monitoring for the detection of occult paroxysmal atrial fibrillation in ischemic stroke of unknown cause. Circulation 124(4):477–486Google Scholar
  22. 22.
    Tani T, Tanabe K, Ono M, Yamaguchi K, Okada M, Sumida T, Konda T, Fujii Y, Kawai J, Yagi T, Sato M, Ibuki M, Katayama M, Tamita K, Yamabe K, Yamamuro A, Nagai K, Shiratori K, Morioka S (2004) Left atrial volume and the risk of paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. J Am Soc Echocardiogr 17:644–648Google Scholar
  23. 23.
    Maron BJ, Haas TS, Maron MS, Lesser JR, Browning JA, Chan RH, Olivotto I, Garberich RF, Schwartz RS (2014) Left atrial remodeling in hypertrophic cardiomyopathy and susceptibility markers for atrial fibrillation identified by cardiovascular magnetic resonance. Am J Cardiol 113(8):1394–1400Google Scholar
  24. 24.
    Tülüce K, Yakar Tülüce S, Yavuzgil O, İsayev E, Bilgin M, Akyıldız Akçay F, Nalbantgil S, Özerkan F (2014) The left atrial phasic functions and the relationship with plasma N-terminal pro-B-type natriuretic peptide levels and symptomatic states in patients with hypertrophic cardiomyopathy. Anadolu Kardiyol Derg 14(8):719–727Google Scholar
  25. 25.
    Bauer F, Shiota T, White RD, Lever HM, Qin JX, Drinko J, Martin M, Tsujino H, Sitges M, Kim YJ, Thomas JD (2004) Determinant of left atrial dilation in patients with hypertrophic cardiomyopathy: a real-time 3-dimensional echocardiographic study. J Am Soc Echocardiogr 17(9):968–975Google Scholar
  26. 26.
    Guttmann OP, Pavlou M, O'Mahony C, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, Garcia-Pavia P, McKenna WJ, Omar RZ, Elliott PM (2017) Hypertrophic cardiomyopathy outcomes investigators. Predictors of atrial fibrillation in hypertrophic cardiomyopathy. Heart 103(9):672–678Google Scholar
  27. 27.
    Siontis KC, Geske JB, Ong K, Nishimura RA, Ommen SR, Gersh BJ (2014) Atrial fibrillation in hypertrophic cardiomyopathy: prevalence, clinical correlations, and mortality in a large high-risk population. J Am Heart Assoc 3(3):e001002Google Scholar
  28. 28.
    Park KM, Im SI, Kim EK, Lee SC, Park SJ, Kim JS, On YK (2016) Atrial fibrillation in hypertrophic cardiomyopathy: is the extent of septal hypertrophy important? PLoS One 11(6):e0156410Google Scholar
  29. 29.
    Cecchi F, Montereggi A, Olivotto I, Marconi P, Dolara A, Maron BJ (1997) Risk for atrial fibrillation in patients with hypertrophic cardiomyopathy assessed by signal averaged P wave duration. Heart 78(1):44–49Google Scholar
  30. 30.
    Ozdemir O, Soylu M, Demir AD, Topaloglu S, Alyan O, Turhan H, Bicer A, Kutuk E (2004) P-wave durations as a predictor for atrial fibrillation development in patients with hypertrophic cardiomyopathy. Int J Cardiol 94(2–3):163–166Google Scholar
  31. 31.
    Rowin EJ, Hausvater A, Link MS, Abt P, Gionfriddo W, Wang W, Rastegar H, Estes NAM, Maron MS, Maron BJ (2017) Clinical profile and consequences of atrial fibrillation in hypertrophic cardiomyopathy. Circulation 136(25):2420–2436Google Scholar
  32. 32.
    Azarbal F, Singh M, Finocchiaro G, Le VV, Schnittger I, Wang P, Myers J, Ashley E, Perez M (2014) Exercise capacity and paroxysmal atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart 100(8):624–630Google Scholar
  33. 33.
    Guttmann OP, Pavlou M, O'Mahony C, Monserrat L, Anastasakis A, Rapezzi C, Biagini E, Gimeno JR, Limongelli G, Garcia-Pavia P, McKenna WJ, Omar RZ, Elliott PM (2015) Hypertrophic cardiomyopathy outcomes investigators. Prediction of thrombo-embolic risk in patients with hypertrophic cardiomyopathy (HCM risk-CVA). Eur J Heart Fail 17(8):837–845Google Scholar
  34. 34.
    Sabzwari SRA, Garg L, Lakkireddy D, Day J (2018) Ten lifestyle modification approaches to treat atrial fibrillation. Cureus 10(5):e2682Google Scholar
  35. 35.
    Wyse DG, Waldo AL, DiMarco JP, Domanski MJ, Rosenberg Y, Schron EB, Kellen JC, Greene HL, Mickel MC, Dalquist JE, Corley SD (2002) Atrial Fibrillation Follow-up Investigation of Rhythm Management (AFFIRM) investigators. A comparison of rate control and rhythm control in patients with atrial fibrillation. N Engl J Med 347(23):1825–1833Google Scholar
  36. 36.
    Al-Khatib SM, NM ALP, Chatterjee R, Crowley MJ, Dupre ME, Kong DF, Lopes RD, Povsic TJ, Raju SS, Shah B, Kosinski AS, AJ MB, Sanders GD (2014) Rate- and rhythm-control therapies in patients with atrial fibrillation: a systematic review. Ann Intern Med 160(11):760–773Google Scholar
  37. 37.
    Andrikopoulos GK, Pastromas S, Flecainide TS (2015) Current status and perspectives in arrhythmia management. World J Cardiol 7(2):76–85Google Scholar
  38. 38.
    Camm AJ, Capucci A, Hohnloser SH, Torp-Pedersen C, Van Gelder IC, Mangal B, Beatch G (2011) AVRO investigators.. A randomized active-controlled study comparing the efficacy and safety of vernakalant to amiodarone in recent-onset atrial fibrillation. J Am Coll Cardiol 57(3):313–321Google Scholar
  39. 39.
    Oral H, Souza JJ, Michaud GF, Knight BP, Goyal R, Strickberger SA, Morady F (1999) Facilitating transthoracic cardioversion of atrial fibrillation with ibutilide pretreatment. N Engl J Med 340(24):1849–1854Google Scholar
  40. 40.
    Connolly SJ, Camm AJ, Halperin JL, Joyner C, Alings M, Amerena J, Atar D, Avezum Á, Blomström P, Borggrefe M, Budaj A, Chen SA, Ching CK, Commerford P, Dans A, Davy JM, Delacrétaz E, Di Pasquale G, Diaz R, Dorian P, Flaker G, Golitsyn S, Gonzalez-Hermosillo A, Granger CB, Heidbüchel H, Kautzner J, Kim JS, Lanas F, Lewis BS, Merino JL, Morillo C, Murin J, Narasimhan C, Paolasso E, Parkhomenko A, Peters NS, Sim KH, Stiles MK, Tanomsup S, Toivonen L, Tomcsányi J, Torp-Pedersen C, Tse HF, Vardas P, Vinereanu D, Xavier D, Zhu J, Zhu JR, Baret-Cormel L, Weinling E, Staiger C, Yusuf S, Chrolavicius S, Afzal R, Hohnloser SH, PALLAS Investigators (2011) Dronedarone in high-risk permanent atrial fibrillation. N Engl J Med 365(24):2268–2276Google Scholar
  41. 41.
    Kirchhof P, Benussi S, Kotecha D, Ahlsson A, Atar D, Casadei B, Castella M, Diener HC, Heidbuchel H, Hendriks J, Hindricks G, Manolis AS, Oldgren J, Popescu BA, Schotten U, Van Putte B, Vardas P, Agewall S, Camm J, Baron Esquivias G, Budts W, Carerj S, Casselman F, Coca A, De Caterina R, Deftereos S, Dobrev D, Ferro JM, Filippatos G, Fitzsimons D, Gorenek B, Guenoun M, Hohnloser SH, Kolh P, Lip GY, Manolis A, McMurray J, Ponikowski P, Rosenhek R, Ruschitzka F, Savelieva I, Sharma S, Suwalski P, Tamargo JL, Taylor CJ, Van Gelder IC, Voors AA, Windecker S, Zamorano JL, Zeppenfeld K (2016) 2016 ESC Guidelines for the management of atrial fibrillation developed in collaboration with EACTS. Eur J Cardiothorac Surg 50(5):e1–e88Google Scholar
  42. 42.
    Vijayaraman P, Chung MK, Dandamudi G, Upadhyay GA, Krishnan K, Crossley G, Bova Campbell K, Lee BK, Refaat MM, Saksena S, Fisher JD, Lakkireddy D (2018) ACC’s electrophysiology council. His Bundle Pacing. J Am Coll Cardiol 72(8):927–947Google Scholar
  43. 43.
    Tendera M, Wycisk A, Schneeweiss A, Poloński L, Wodniecki J (1993) Effect of sotalol on arrhythmias and exercise tolerance in patients with hypertrophic cardiomyopathy. Cardiology 82(5):335–342Google Scholar
  44. 44.
    Singh S, Zoble RG, Yellen L, Brodsky MA, Feld GK, Berk M, Billing CB Jr (2000) Efficacy and safety of oral dofetilide in converting to and maintaining sinus rhythm in patients with chronic atrial fibrillation or atrial flutter: the symptomatic atrial fibrillation investigative research on dofetilide (SAFIRE-D) study. Circulation 102(19):2385–2390Google Scholar
  45. 45.
    Torp-Pedersen C, Møller M, Bloch-Thomsen PE, Køber L, Sandøe E, Egstrup K, Agner E, Carlsen J, Videbaek J, Marchant B, Camm AJ (1999) Dofetilide in patients with congestive heart failure and left ventricular dysfunction. Danish investigations of arrhythmia and mortality on Dofetilide Study Group. N Engl J Med 341(12):857–865Google Scholar
  46. 46.
    Moore JC, Trager L, Anzia LE, Saliba W, Bassiouny M, Bhargava M, Chung M, Desai M, Garberich R, Lever H, Lindsay BD, Sengupta J, Tchou P, Wazni O, Wilkoff BL (2018) Dofetilide for suppression of atrial fibrillation in hypertrophic cardiomyopathy: a case series and literature review. Pacing Clin Electrophysiol 41(4):396–401Google Scholar
  47. 47.
    Singh BN, Singh SN, Reda DJ, Tang XC, Lopez B, Harris CL, Fletcher RD, Sharma SC, Atwood JE, Jacobson AK, Lewis HD Jr, Raisch DW, Ezekowitz MD, Sotalol Amiodarone Atrial Fibrillation Efficacy Trial (SAFE-T) investigators (2005) Amiodarone versus sotalol for atrial fibrillation. N Engl J Med 352(18):1861–1872Google Scholar
  48. 48.
    Saksena S, Slee A, Waldo AL, Freemantle N, Reynolds M, Rosenberg Y, Rathod S, Grant S, Thomas E, Wyse DG (2011) Cardiovascular outcomes in the AFFIRM Trial (Atrial Fibrillation Follow-Up Investigation of Rhythm Management). An assessment of individual antiarrhythmic drug therapies compared with rate control with propensity score-matched analyses. J Am Coll Cardiol 58(19):1975–1985Google Scholar
  49. 49.
    Ahmed S, Rienstra M, Crijns HJ, Links TP, Wiesfeld AC, Hillege HL, Bosker HA, Lok DJ, Van Veldhuisen DJ, Van Gelder IC, CONVERT Investigators (2008) Continuous vs episodic prophylactic treatment with amiodarone for the prevention of atrial fibrillation: a randomized trial. JAMA 300(15):1784–1792Google Scholar
  50. 50.
    Bunch TJ, Munger TM, Friedman PA, Asirvatham SJ, Brady PA, Cha YM, Rea RF, Shen WK, Powell BD, Ommen SR, Monahan KH, Haroldson JM, Packer DL (2008) Substrate and procedural predictors of outcomes after catheter ablation for atrial fibrillation in patients with hypertrophic cardiomyopathy. J Cardiovasc Electrophysiol 19(10):1009–1014Google Scholar
  51. 51.
    Santangeli P, Di Biase L, Themistoclakis S, Raviele A, Schweikert RA, Lakkireddy D, Mohanty P, Bai R, Mohanty S, Pump A, Beheiry S, Hongo R, Sanchez JE, Gallinghouse GJ, Horton R, Dello Russo A, Casella M, Fassini G, Elayi CS, Burkhardt JD, Tondo C, Natale A (2013) Catheter ablation of atrial fibrillation in hypertrophic cardiomyopathy: long-term outcomes and mechanisms of arrhythmia recurrence. Circ Arrhythm Electrophysiol 6(6):1089–1094Google Scholar
  52. 52.
    Zhao DS, Shen Y, Zhang Q, Lin G, Lu YH, Chen BT, Shi LS, Huang JF, Lu HH (2016) Outcomes of catheter ablation of atrial fibrillation in patients with hypertrophic cardiomyopathy: a systematic review and meta-analysis. Europace 18(4):508–520Google Scholar
  53. 53.
    Hussein AA, Saliba WI, Barakat A, Bassiouny M, Chamsi-Pasha M, Al-Bawardy R, Hakim A, Tarakji K, Baranowski B, Cantillon D, Dresing T, Tchou P, Martin DO, Varma N, Bhargava M, Callahan T, Niebauer M, Kanj M, Chung M, Natale A, Lindsay BD, Wazni OM (2016) Radiofrequency ablation of persistent atrial fibrillation: diagnosis-to-ablation time, markers of pathways of atrial remodeling, and outcomes. Circ Arrhythm Electrophysiol 9(1):e003669Google Scholar
  54. 54.
    Walters TE, Nisbet A, Morris GM, Tan G, Mearns M, Teo E, Lewis N, Ng A, Gould P, Lee G, Joseph S, Morton JB, Zentner D, Sanders P, Kistler PM, Kalman JM (2016) Progression of atrial remodeling in patients with high-burden atrial fibrillation: implications for early ablative intervention. Heart Rhythm 13(2):331–339Google Scholar
  55. 55.
    Bassiouny M, Lindsay BD, Lever H, Saliba W, Klein A, Banna M, Abraham J, Shao M, Rickard J, Kanj M, Tchou P, Dresing T, Baranowski B, Bhargava M, Callahan T, Tarakji K, Cantillon D, Hussein A, Marc Gillinov A, Smedira NG, Wazni O (2015) Outcomes of nonpharmacologic treatment of atrial fibrillation in patients with hypertrophic cardiomyopathy. Heart Rhythm 12(7):1438–1447Google Scholar
  56. 56.
    Chen MS, McCarthy PM, Lever HM, Smedira NG, Lytle BL (2004) Effectiveness of atrial fibrillation surgery in patients with hypertrophic cardiomyopathy. Am J Cardiol 93(3):373–375Google Scholar
  57. 57.
    Quintana E, Cox JL (2017) Surgical management of atrial fibrillation at the time of septal myectomy. Ann Cardiothorac Surg 6(4):386–393Google Scholar
  58. 58.
    January CT, Wann LS, Alpert JS et al (2014) AHA/ACC/HRS guideline for the management of patients with atrial fibrillation: a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the Heart Rhythm Society. Circulation 130(23):e199Google Scholar
  59. 59.
    Maron BJ, Olivotto I, Bellone P, Conte MR, Cecchi F, Flygenring BP, Casey SA, Gohman TE, Bongioanni S, Spirito P (2002) Clinical profile of stroke in 900 patients with hypertrophic cardiomyopathy. J Am Coll Cardiol 39(2):301–307Google Scholar
  60. 60.
    Holmes DR, Reddy VY, Turi ZG, Doshi SK, Sievert H, Buchbinder M, Mullin CM, Sick P, PROTECT AF Investigators (2009) Percutaneous closure of the left atrial appendage versus warfarin therapy for prevention of stroke in patients with atrial fibrillation: a randomised non-inferiority trial. Lancet 374(9689):534–542Google Scholar
  61. 61.
    Katz ES, Tsiamtsiouris T, Applebaum RM, Schwartzbard A, Tunick PA, Kronzon I (2000) Surgical left atrial appendage ligation is frequently incomplete: a transesophageal echocardiograhic study. J Am Coll Cardiol 36(2):468–471Google Scholar
  62. 62.
    Haruki S, Minami Y, Hagiwara N (2016) Stroke and Embolic events in hypertrophic cardiomyopathy: risk stratification in patients without atrial fibrillation. Stroke 47(4):936–942.  https://doi.org/10.1161/STROKEAHA.115.012130 Google Scholar
  63. 63.
    Sanna T, Diener HC, Passman RS, Di Lazzaro V, Bernstein RA, Morillo CA, Rymer MM, Thijs V, Rogers T, Beckers F, Lindborg K, Brachmann J, CRYSTAL AF Investigators (2014) Cryptogenic stroke and underlying atrial fibrillation. N Engl J Med 370(26):2478–2486Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2018

Authors and Affiliations

  1. 1.Division of CardiologyLehigh Valley Health NetworkAllentownUSA
  2. 2.Maulana Azad Medical CollegeDelhiIndia
  3. 3.Division of CardiologyBrown UniversityProvidenceUSA
  4. 4.Department of Internal MedicineThe University of Tennessee Health Science CenterMemphisUSA

Personalised recommendations